244 related articles for article (PubMed ID: 26502856)
1. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
Liu JW; Zuo XL; Wang S
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(19):3655-73. PubMed ID: 26502856
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.
Jia X; Liu J; Gao Y; Huang Y; Du Z
Arch Med Res; 2014 Oct; 45(7):580-8. PubMed ID: 25446613
[TBL] [Abstract][Full Text] [Related]
3. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
Xu C; Yan Z; Zhou L; Wang Y
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
[TBL] [Abstract][Full Text] [Related]
4. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.
Xu D; Su C; Sun L; Gao Y; Li Y
Ann Hepatol; 2019; 18(1):58-67. PubMed ID: 31113610
[TBL] [Abstract][Full Text] [Related]
5. The Value of GPC3 and GP73 in Clinical Diagnosis of Hepatocellular Carcinoma.
Jing JS; Ye W; Jiang YK; Ma J; Zhu MQ; Ma JM; Zhou H; Yu LQ; Yang YF; Wang SC
Clin Lab; 2017 Nov; 63(11):1903-1909. PubMed ID: 29226636
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
7. Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature.
Yang SL; Fang X; Huang ZZ; Liu XJ; Xiong ZF; Liu P; Yao HY; Li CH
Dis Markers; 2014; 2014():127831. PubMed ID: 25378766
[TBL] [Abstract][Full Text] [Related]
8. Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.
Tahon AM; El-Ghanam MZ; Zaky S; Emran TM; Bersy AM; El-Raey F; A Z E; El Kharsawy AM; Johar D
J Gastrointest Cancer; 2019 Sep; 50(3):434-441. PubMed ID: 29623600
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
10. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma.
Attallah AM; El-Far M; Omran MM; Abdelrazek MA; Attallah AA; Saeed AM; Farid K
Tumour Biol; 2016 Sep; 37(9):12571-12577. PubMed ID: 27380057
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer.
Liu S; Wang M; Zheng C; Zhong Q; Shi Y; Han X
Clin Biochem; 2020 May; 79():54-60. PubMed ID: 32087138
[TBL] [Abstract][Full Text] [Related]
14. Serological tumor markers of hepatocellular carcinoma: a meta-analysis.
Hussein TD
Int J Biol Markers; 2015 Feb; 30(1):e32-42. PubMed ID: 25450646
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis.
Liu XF; Hu ZD; Liu XC; Cao Y; Ding CM; Hu CJ
Clin Biochem; 2014 Feb; 47(3):196-200. PubMed ID: 24362268
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
17. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
[TBL] [Abstract][Full Text] [Related]
18. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
20. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
